Moderna Inc (MRNA)
Return on equity (ROE)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (ttm) | US$ in thousands | -3,561,000 | -2,224,000 | -5,867,000 | -5,968,000 | -4,714,000 | -3,466,000 | 1,207,000 | 4,784,000 | 8,362,000 | 11,765,000 | 14,055,000 | 14,638,000 | 12,202,000 | 7,061,515 | 3,494,879 | 598,166 | -747,064 | -598,819 | -488,377 | -506,718 |
| Total stockholders’ equity | US$ in thousands | 10,901,000 | 11,927,000 | 11,712,000 | 12,817,000 | 13,854,000 | 13,455,000 | 16,949,000 | 18,863,000 | 19,123,000 | 17,992,000 | 17,985,000 | 17,075,000 | 14,145,000 | 10,124,000 | 6,704,000 | 3,838,000 | 2,561,000 | 2,759,800 | 2,946,880 | 1,640,870 |
| ROE | -32.67% | -18.65% | -50.09% | -46.56% | -34.03% | -25.76% | 7.12% | 25.36% | 43.73% | 65.39% | 78.15% | 85.73% | 86.26% | 69.75% | 52.13% | 15.59% | -29.17% | -21.70% | -16.57% | -30.88% |
December 31, 2024 calculation
ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-3,561,000K ÷ $10,901,000K
= -32.67%
Moderna Inc's return on equity (ROE) has exhibited significant fluctuations over the reported periods. The ROE was negative for most of 2020 and the first half of 2021, indicating that the company was not generating positive returns for its shareholders relative to their equity investments.
However, starting from March 31, 2021, the ROE turned positive and began to improve steadily throughout 2021 and the first half of 2022, reaching impressive levels by December 31, 2021. This could suggest that Moderna Inc was effectively utilizing its equity to generate profits for its shareholders during this period.
Subsequently, the ROE showed some fluctuations, but remained generally positive until September 30, 2023, where it turned negative again. This negative trend continued through the end of 2024. The declining ROE in the latter part of the data may indicate challenges in profitability or efficiency in leveraging equity to generate returns for shareholders.
Overall, while Moderna Inc experienced a positive turnaround in ROE from 2021 to 2022, the subsequent decline in ROE highlights the importance of monitoring and analyzing this ratio as it can signify changes in the company's profitability and efficiency in utilizing shareholder equity.
Peer comparison
Dec 31, 2024